|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension
1 Dept of Internal Medicine, Division of Cardiology, 2 Division of Pulmonary and Critical Care Medicine and 3 Centre for Biostatistics, University of Michigan
CORRESPONDENCE: M. Rubenfire, University of Michigan, 24 Frank Lloyd Wright Drive, 48106, Ann Arbor, MI, USA. Fax: 01 7349987456
Keywords: mortality, oximetry, pulmonary hypertension
Received: January 12, 2000
Accepted October 26, 2000
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionReferences |
|---|
There are no reliable predictors of mortality in primary pulmonary hypertension (PPH). This study assessed whether exercise oxygen desaturation and distance achieved during a six-minute walk are associated with mortality in moderately symptomatic patients with PPH.
Thirty-four patients with PPH underwent a pretreatment six-minute walk test, and an invasive haemodynamic assessment of pulmonary vasodilator reserve, to select the best treatment option (epoprostenol in 27 and nifedipine in 7). Median follow-up was 26 months (12 months for the nonsurvivors was 26%), and median survival, >46 months by Kaplan-Maier estimate.
The mean±sd distance walked was 275±155 m and reduction in arterial oxygen saturation (Sa,O2) at maximal distance (
Sa,O2) was 8.4±4.5%. A distance 
300 m increased mortality risk by 2.4, and a Sa,O2 of 
10 % increased mortality risk by 2.9. Only Sa,O2 at peak distance, Sa,O2 and pulmonary vascular resistance (PVR) were related to mortality. After adjusting for PVR, there remained a 27% increase in risk of death for each per cent decrease in Sa,O2.
The six-minute walk distance and exercise oxygen saturation may be helpful in selecting patients with primary pulmonary hypertension for whom transplant listing is appropriate.
Primary pulmonary hypertension (PPH) is characterized by a progressive increase in pulmonary vascular resistance (PVR) and a near universally fatal outcome 1, 2. Epoprostenol 3, 4 and oral calcium channel blocking agents 5 can improve the clinical course in PPH, but the long-term prognosis remains relatively poor and the rate of deterioration is not readily predicted from clinical parameters. Neither symptom relief, nor initial reduction in PVR assures a good long-term prognosis 2.
In congestive heart failure 6, 7 and chronic pulmonary diseases 8, 9 the six-minute walk test has gained increasing acceptance as a simple tool to assess functional capacity. Furthermore, the level of desaturation during the walk correlates with the degree of impairment of both heart and lung function 10, 11. A prospective study was therefore designed to determine whether the distanced walked and/or the arterial oxygen desaturation on a pretreatment six-minute walk test is associated with an increase in mortality in moderately symptomatic PPH.
|
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
Study population
Fifty-four patients diagnosed with PPH 1992–1997 in the University of Michigan Pulmonary Hypertension Center were evaluated. PPH was defined by a mean pulmonary artery pressure (mPAP) >25 mmHg after exclusion of secondary causes such as pulmonary embolus, collagen vascular disease, sleep apnoea, lung disease, and congenital, valvular, or other heart disease, with the exception of atrial septal defect without left to right shunt 12. One patient had portal-pulmonary hypertension. Seventeen patients were excluded for the following reasons: previous treatment with calcium channel blockers or intravenous (i.v.) epoprostenol, and New York Heart Association (NYHA) class IV or orthopaedic issues precluding the walk. Patients with pulmonary veno-occlusive disease or human immunodeficiency virus were also excluded.
The thirty-four eligible patients underwent a detailed examination, pulmonary function testing, and a standardized six-minute test with monitoring of arterial oxygen saturation (Sa,O2). Right heart catheterization with assessment of pulmonary vasodilator reserve was used to determine the best treatment strategy in all patients. Pulmonary vasodilator reserve was determined by the response to 5 min inhaled nitric oxide (80 parts per million) (as described by Ricciardi et al. 13) in 24 subjects, incremental doses of intravenous adenosine (as described by Schrader et al. 14) in 6 subjects, and incremental doses of short acting nifedipine (as described by Rich et al. 15) in seven subjects. Patients with pulmonary vasodilator reserve, defined as a decrease in mPAP and/or PVR by 20% with inhaled nitric oxide or i.v. adenosine, underwent a subsequent trial of short acting nifedipine 13. Those with pulmonary vasodilator reserve following short acting nifedipine were placed on sustained release nifedipine, and the remaining were treated with continuous i.v. epoprostenol.
Seven patients were treated with nifedipine only. In 23 patients the initial treatment was intravenous epoprostenol, and in four epoprostenol was utilized following deterioration on high dose nifedipine (nifedipine was discontinued). One patient died shortly after a double lung transplant. The mean±sd dose of nifedipine was 220±92 mg. Epoprostenol was administered via an indwelling Hickman catheter, initially titrated to symptom tolerance without hypotension. The usual starting dose was 4–6 ng·kg–1·min–1. The dose was adjusted regularly with the mean dosage increased by 1–2 ng·kg–1·min–1, every 2 weeks for the first 6 months, then monthly according to symptoms and side effects. Patients were encouraged to tolerate common side effects such as jaw claudication and flushing.
Standard treatment included digoxin (levels measured at three month intervals) and sodium warfarin, adjusted to an international normalized ratio of 2–3 with nifedipine and 1.5–2 with epoprostenol. Diuretics (furosemide and spironolactone) were used to control oedema and ascites. Patients <60 yrs of age were referred for lung transplant.
Pulmonary function
Pulmonary function tests were measured with a 1070 Hans Rudolf pneumotachograph (Medical Graphics Co, St. Paul, MN, USA) and corrected for temperature and barometric pressure 16. Arterial blood gases were drawn from the radial artery on room-air prior to the pulmonary function and six-minute walk tests, and measured by standard gas analysis (Radiometer, ABL 520, Radiometer America Inc., Westlake, OH, USA).
The six-minute walk test and arterial pulse oximetry
The six-minute walk was administered a minimum of 2 h after the pulmonary function test by a certified technician, unaware of the results, using a protocol similar to that of Sciurba et al. 9. Briefly, the patients walked on a level circular surface with a length of 42 m, with standardized instructions including to walk as quickly and comfortably possible for 6 min without running, and gently encouraged using set phrases every 30 seconds 7, 9, 17.
Cutaneous Sa,O2 was assessed at baseline and during the walk by a continuous pulse oximeter (Nellcor N-3000, Mallinckrodt Inc., Hazelwood, MO, USA) using the finger or ear. The test was stopped for safety purposes if the Sa,O2 dropped <86% with the exception of patients with an atrial level right to left shunt 18. The walk was repeated with oxygen supplementation in those with resting or exercise Sa,O2 <90% to determine the need and dosage for supplemental oxygen.
The baseline arterial oxygen saturation (Sa,O2-rest), the minimal exercise arterial oxygen saturation sustained for >10 s (Sa,O2-exercise), the change (decrease) during the walk (Sa,O2-rest – Sa,O2-exercise = Sa,O2) and the distance walked were recorded and calculated.
Haemodynamic assessment
Right heart catheterization was performed via the internal jugular or femoral vein in the fasting state. A four-lumen (additional lumen for stiffening wire) balloon flotation catheter was used for thermodilution cardiac output (CO), and sampling of mixed venous oxygen saturation and pressures. Brachial artery pressure was measured by an automated noninvasive cuff using Doppler signals, or via the radial or femoral artery when systolic pressure was <100 mmHg. Mean pressures were derived electronically. The following haemodynamic parameters were measured and/or calculated: systolic, diastolic, and mean pulmonary artery pressures and right atrial pressure (sPAP, dPAP, mPAP, and mRAP, respectively), CO, pulmonary capillary wedge (PCW) and PVR (mPAP–PCW)/CO) in Wood units.
Statistical methods
Continuous variables are presented as mean±sd, and counts and percentages given for categorical variables. Categorical comparisons were performed by Chi-squared and continuous data by unpaired t-tests. The statistical significance level was set at p<0.05.
Survival analysis was used to analyse the time to death data from the time of initial diagnosis. The survival distribution was estimated using the Kaplan-Meier estimator with censoring of transplanted cases at time of lung transplant. The effects of covariates on survival time were tested using Cox regression. Because there were only nine deaths, one variable at a time was entered in the Cox model. Hazard ratios, the incremental risk or odds of death attributable to having versus not having a parameter, and corresponding confidence intervals, were computed. For continuous variables, hazard ratios are expressed in terms of meaningful units of measurement. The median follow-up time was estimated using the Kaplan-Meier method with censoring as the endpoint and deaths and time of lung transplant considered censored values.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
Demographic and clinical parameters
Twenty-eight of the 34 patients were female. The mean age was 44.3±11.9 yrs (range 23–67 yrs). There was no age or sex difference between survivors and nonsurvivors. Seven were NYHA class II at baseline (2 nonsurvivors) and 27 NYHA class III (7 nonsurvivors). The mean time from initial symptoms to diagnosis was 17.8±13 months (median 12 months, range 1–60 months). The commonest symptom was dyspnoea on exertion (94%). Most patients had other symptoms including fatigue (21%), light-headedness (24%), palpitations (24%), oedema (18%), syncope (15%) and chest pain (6%).
Haemodynamic, pulmonary function, and blood gas parameters
The initial baseline haemodynamic parameters are summarized and displayed by NYHA class and survivors versus nonsurvivors in table 1
. The mRAP was 12.5±6.3 mmHg, mPAP 56.9±12.1 mmHg, CO 3.9±1.5 L·min–1, and PVR 12.9±5.3 Wood units. There was no statistical difference in haemodynamic parameters between survivors and nonsurvivors or between NYHA class II and class III, with the exception of PVR, which was higher in nonsurvivors (15.5±6.0 Wood units versus 11.9±4.7 Wood units, p=0.04).
|
The pulmonary function tests were normal in 55% of patients. Thirty two per cent of patients had a restrictive pattern, 13% an obstructive pattern, and carbon monoxide diffusion capacity (DL,CO) was <70% in 45% of patients. There was no sex difference in pulmonary function abnormalities. The majority of patients had one or more abnormalities in resting blood gases. Seventy-seven per cent of the patients were hypoxaemic (PO2 <70 mmHg), 59% hypocapnic (PCO2 <35 mmHg), and respiratory alkalosis (pH >7.44) was present in 56% of patients. The mean Sa,O2 determined from the arterial PO2 after correcting for pH was 91.7±4.2%.
Exercise oximetry and distance on the six-minute walk test
The oximetry and distances walked are summarized in table 2 and presented by NYHA class and survival. The peak distance walked was 275±155 m, less in males than females (183±80 m versus 290±160 m, p<0.05), and greater in NYHA class II than NYHA class III (352±196 m versus 255±141 m, p=0.05).
|
Only ten patients (29%) walked for the 6 min. Twenty-four (71%) were stopped due to an Sa,O2-exercise
86%. The Sa,O2-rest was <94% in eight patients (23.5%) with a mean of 94.8±4.7%, and at peak distance decreased below normal (decrease >4 %) in 27 patients (79%). The mean Sa,O2-exercise was 87.4±7.1%, a decrease of 8.5±4.5 %, which was worse in males than females (males=11.5±6.2% versus females= 7.8±4.0%, p=0.03). The eighteen patients who desaturated by <10% achieved a peak distance of <300 m, and 78% of them had no intracardiac shunt by contrast echo-Doppler.
Description of nonsurvivors
Two deaths occurred during the first year and seven during the second yr following diagnosis. In the nine nonsurvivors, treatment was epoprostenol in six; epoprostenol after nifedipine failure in two, and nifedipine in one. Two deaths occurred despite atrial septostomy and extra corporal membrane oxygenation (ECMO) support, and one following a double lung transplant.
Survival results
Twenty-five (74%) were considered survivors at the time of analysis. The median follow-up time was 26 months (12 months for deceased and 46 months for survivors). Figure 1 is the Kaplan-Meier estimate of survival function in months from diagnosis. The 25th percentile of survival time was 21 months, with a median survival of >46 months.
|
The variables entered into the Cox model, to identify those related to survival time, are presented in table 3
. The only significant variables were Sa,O2-exercise, the decrease in Sa,O2-exercise (Sa,O2) and PVR. There was a 26% increase in risk of death for each percent decrease in oxygen saturation, p=0.02. The significance of Sa,O2 was not diminished after adjustment for haemodynamic variables (mRAP, mPAP, CO, PVR) or NYHA class. After adjustment for PVR, the effect of Sa,O2 was essentially unchanged. There was a 16% increase in risk of death for each Wood unit increase in PVR (p=0.04). After adjusting for Sa,O2, the effect of PVR was slightly diminished (p=0.06).
|
The total distance walked was associated with a better prognosis. An 18% reduction in risk of death occurred with each 50 m increase in distance (p=0.11). After adjusting for
Sa,O2 in the Cox regression, distance walked was not associated with death (p=0.3), but after adjusting for distance walked the Sa,O2 remained significant (p<0.05). There was no significant relationship between slow vital capacity (SVC), forced vital capacity (FVC), the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC), DL,CO, or arterial pH, PCO2, or PO2 and mortality. The presence of an intra-atrial right to left shunt (2 atrial septal defects and 4 patent foramen ovale) was not associated with death, and the increase in mortality associated with increasing exercise oxygen desaturation remained after adjusting for possible intracardiac shunting (p=0.056). Mortality also remained elevated after adjustment for NYHA class III, but the population size was insufficient to determine the relationship between Sa,O2-exercise and mortality in NYHA class II.
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
It was hypothesized that the degree of arterial desaturation and distance achieved on a standardized six-minute walk test would complement other clinical and haemodynamic parameters for identifying patients at risk of death in PPH. In this study of 34 patients with PPH, of whom 27 were treated with epoprostenol, the mortality was 26.5% and all deaths occurred within the 2 yrs of diagnosis. The lone clinical, pulmonary, and haemodynamic parameters associated with survival time were the decrease in Sa,O2 with exercise and PVR. There was a 26% increase in risk of death for each per cent decrease in Sa,O2. The decrease or change in Sa,O2 between rest and peak-exercise time (mean
Sa,O2 of 8.65±4.55%) was comparable to patients with moderately severe chronic obstructive pulmonary disease 6 Further, exercise arterial desaturation remained significant after adjustment for distance and haemodynamic parameters. The results are particularly striking, since NYHA class IV patients were included. The mean pretreatment distance walked was 275± 155 m, comparable to previous reports 4, 19, 20. As in the study of Kadikar et al. 19, a trend, but no significant relationship was found, between decreasing distance walked pretreatment and risk of mortality. In contrast, in patients tested on treatment (38 of 43 on prostacyclin derivatives) Miyamoto et al. 20 found a distance of <332 m on the six-minute walk test was associated with decrease in survival. That the ontreatment but not pretreatment distance walked would correlate with outcome is consistent with the improved prognosis attributable to prostacyclin. It is possible the pretreatment distance would correlate better with mortality in a larger cohort of patients than the present study.
In the United States National Institutes of Health PPH registry, which included NYHA class IV subjects, there was a correlation between reduced FVC and decreased DL,CO and poor survival 1. The present authors could not identify a significant correlation between any spirometric variable and survival time, suggesting that when abnormal, these parameters are reflective of adverse haemodynamic indices. The reduction in DL,CO found in 45% of patients in this study is consistent with the obliteration of small pulmonary arteries and low cardiac output.
Implications of findings
The median survival time following diagnosis in the PPH National Institutes of Health Registry was 2.8 yrs 1. Epoprostenol and treatment based upon invasive haemodynamic parameters and pulmonary vasodilator reserve are major advances in the management of a nearly uniformly fatal disease. However, a group remains with an unfavourable response to treatment for whom transplantation is the only viable option 1, 21, 22. Therapeutic decisions are complicated by the inaccuracy of risk predictors, which have not been validated in the epoprostenol era 1, 22, 23. Considering the present findings, the clinical assessment of PPH patients for listing for transplant should include both the oxygen desaturation and distance achieved on the six-minute walk test 19.
Limitations of this study
While the size of this study is limited, that each patient was cared for with a standardized protocol by a multidisciplinary team in an experienced regional centre lends strength to the observations. The patients are typical of PPH in the US regarding clinical, pulmonary, and haemodynamic parameters, and available treatment options. Eligible patients were listed for lung transplant, but as elsewhere, the regional time for receiving a lung during the study period was over 18 months and precluded this option in eight of the nine deaths.
Methods used for the six-minute walk test vary, but the one employed in this series is similar to recent recommendations 9, 18. The standardized protocol requires three sessions to obtain optimal reproducibility 9, but the need to begin treatment precluded us from retesting. To reduce the impact of test variability, patients were educated with a short introductory walk and rested for 1 h. Importantly, while experience could impact the distance walked, it would have no influence on the degree of desaturation, which was the major significant outcome variable.
The present data suggest that a pretreatment six-minute walk test may be a useful adjunct in the functional evaluation of patients with primary pulmonary hypertension. The utility of arterial oxygen desaturation is independent of New York Heart Association (class II and III) and remains significant after correction for haemodynamic parameters. If the current findings can be validated in a larger multi-institutional cohort, more accurate and appropriate risk stratification and selection of patients for lung or heart-lung transplant in primary pulmonary hypertension will become feasible.
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
- D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
- Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.
[Free Full Text] - Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485–491.
- Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409–415.
[Abstract/Free Full Text] - Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.[Abstract]
- Guyatt GH, Thompson PJ, Berman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis 1985;38:517–524.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
- Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919–923.[Abstract]
- Steel B. Timed walking tests of exercise capacity in chronic cardiopulmonary illness. J Cardiopulmonary Rehab 1996;16:251–257.[CrossRef][Medline] [Order article via Infotrieve]
- Sciurba F, Slivka W. Six-minute walk testing. Semin Resp and Crit Care Med 1998;19:383–392.
- Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996;110:325–332.
[Abstract/Free Full Text] - Efthimiou J, Mounsey PJ, Benson DN, Madgwick R, Coles SJ, Benson MK. Effect of carbohydrate rich versus fat rich loads on gas exchange and walking performance in patients with chronic obstructive lung disease. Thorax 1992;4:451–456.
- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216–223.
- Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32:1068–1073.
[Abstract/Free Full Text] - Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060–1064.[Abstract]
- Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991;18:1323–1327.[Abstract]
- Crapo RO. Pulmonary-function testing. N Engl J Med 1994;331:25–30.
[Free Full Text] - Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax 1984;39:818–822.
[Abstract/Free Full Text] - Foss C. Pulse Oximetry with Exercise: Assessment of Desaturation, Oxygen Titration and Distance Walked. In: Wanger J, ed. Pulmonary Function and Laboratory Management and Procedural Manual: American Thoracic Society; 1998.
- Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997;16:313–319.[Web of Science][Medline] [Order article via Infotrieve]
- Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–492.
[Abstract/Free Full Text] - Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302.
[Abstract/Free Full Text] - Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994;89:1733–1744.
[Abstract/Free Full Text] - Nootens M, Freels S, Kaufmann E, Levy PS, Rich S. Timing of single lung transplantation for primary pulmonary hypertension. J Heart Lung Transplant 1994;13:276–281.[Web of Science][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
|
|
 |
|
  A. J. Peacock, R. Naeije, N. Galie, and L. Rubin End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J., July 1, 2009; 34(1): 231 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Salzman The 6-Min Walk Test: Clinical and Research Role, Technique, Coding, and Reimbursement Chest, May 1, 2009; 135(5): 1345 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Minniti, C. Sable, A. Campbell, S. Rana, G. Ensing, N. Dham, O. Onyekwere, M. Nouraie, G. J. Kato, M. T. Gladwin, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation Haematologica, March 1, 2009; 94(3): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. PAMIDI and S. MEHTA Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts? J Rheumatol, February 1, 2009; 36(2): 216 - 218. [Full Text] [PDF]
|
|
|
|
|
|
M. C. GARIN, K. B. HIGHLAND, R. M. SILVER, and C. STRANGE Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma J Rheumatol, February 1, 2009; 36(2): 330 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Casanova, C. Cote, J. M. Marin, V. Pinto-Plata, J. P. de Torres, A. Aguirre-Jaime, C. Vassaux, and B. R. Celli Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD Chest, October 1, 2008; 134(4): 746 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Impens, S. Wangkaew, and J. R. Seibold The 6-minute walk test in scleroderma--how measuring everything measures nothing Rheumatology, October 1, 2008; 47(suppl_5): v68 - v69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bourbonnais and L. Samavati Clinical predictors of pulmonary hypertension in sarcoidosis Eur. Respir. J., August 1, 2008; 32(2): 296 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Edelman Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Montani, R. Souza, C. Binkert, W. Fischli, G. Simonneau, M. Clozel, and M. Humbert Endothelin-1/Endothelin-3 Ratio: A Potential Prognostic Factor of Pulmonary Arterial Hypertension Chest, January 1, 2007; 131(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients Chest, January 1, 2007; 131(1): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Provencher, D. Chemla, P. Herve, O. Sitbon, M. Humbert, and G. Simonneau Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension Eur. Respir. J., January 1, 2006; 27(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. White, N. Terrin, K. B. Miller, and H. F. Ryan Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation Chest, July 1, 2005; 128(1): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Jounieaux, D. Rose, and P. Aubry Relationships between exercise-induced pulmonary hypertension and nocturnal desaturation Eur. Respir. J., June 1, 2005; 25(6): 1126 - 1127. [Full Text] [PDF]
|
|
|
|
|
|
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra Pulmonary Arterial Hypertension: The Key Role of Echocardiography Chest, May 1, 2005; 127(5): 1836 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
|
|
M. McGoon, D. Gutterman, V. Steen, R. Barst, D. C. McCrory, T. A. Fortin, and J. E. Loyd Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 14S - 34S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 78S - 92S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Barst, M. McGoon, A. Torbicki, O. Sitbon, M. J. Krowka, H. Olschewski, and S. Gaine Diagnosis and differential assessment of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 40S - 47S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. N. Lama, K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, Q. Long, S. Murray, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al. Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1084 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-G. Sun, J. E. Hansen, R. J. Oudiz, and K. Wasserman Gas Exchange Detection of Exercise-Induced Right-to-Left Shunt in Patients With Primary Pulmonary Hypertension Circulation, January 1, 2002; 105(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |